Income Tax Expense (Benefit) of Fusion Pharmaceuticals Inc. from 30 Jun 2019 to 31 Mar 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary: Fusion Pharmaceuticals Inc. quarterly and annual Income Tax Expense (Benefit) in USD history and change rate from 30 Jun 2019 to 31 Mar 2024.
Fusion Pharmaceuticals Inc. Income Tax Expense (Benefit) for the quarter ending 31 Mar 2024 was $237,000, a 2055% decline year-over-year.
Fusion Pharmaceuticals Inc. Income Tax Expense (Benefit) for the twelve months ending 31 Mar 2024 was $561,000.
Fusion Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2023 was $787,000.
Fusion Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2022 was $1,837,000, a 1457% decline from 2021.
Fusion Pharmaceuticals Inc. annual Income Tax Expense (Benefit) for 2021 was $118,000, a 105% decline from 2020.
Source SEC data: View on sec.gov

Income Tax Expense (Benefit), Trailing 12 Months (USD)

Income Tax Expense (Benefit), Quarterly (USD)

Income Tax Expense (Benefit), YoY Quarterly Change (%)

Income Tax Expense (Benefit), Annual (USD)

Income Tax Expense (Benefit), YoY Annual Change (%)

Fusion Pharmaceuticals Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q1 2024	$561,000	$237,000	-$226,000	-2055%	01 Jan 2024	31 Mar 2024	10-Q	07 May 2024	2024	Q1
Q4 2023	$787,000	$1,296,000	+$1,636,000		01 Oct 2023	31 Dec 2023	10-K	20 Mar 2024	2023	Q4
Q3 2023	$849,000	$253,000	+$508,000	+67%	01 Jul 2023	30 Sep 2023	10-Q	07 Nov 2023	2023	Q3
Q2 2023	$1,357,000	$245,000	+$436,000	+64%	01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2023	2023	Q2
Q1 2023	$1,793,000	$11,000	+$44,000	+80%	01 Jan 2023	31 Mar 2023	10-Q	07 May 2024	2024	Q1
Q4 2022	$1,837,000	$340,000	-$167,000	-97%	01 Oct 2022	31 Dec 2022	10-K	20 Mar 2024	2023	Q4
Q3 2022	$1,670,000	$761,000	-$809,000	-1685%	01 Jul 2022	30 Sep 2022	10-Q	07 Nov 2023	2023	Q3
Q2 2022	$861,000	$681,000	-$695,000	-4964%	01 Apr 2022	30 Jun 2022	10-Q	08 Aug 2023	2023	Q2
Q1 2022	$166,000	$55,000	-$48,000	-686%	01 Jan 2022	31 Mar 2022	10-Q	11 May 2023	2023	Q1
Q4 2021	$118,000	$173,000	-$2,757,000	-107%	01 Oct 2021	31 Dec 2021	10-K	16 Mar 2023	2022	Q4
Q3 2021	$2,639,000	$48,000	+$233,000		01 Jul 2021	30 Sep 2021	10-Q	08 Nov 2022	2022	Q3
Q2 2021	$2,406,000	$14,000	-$136,000	-91%	01 Apr 2021	30 Jun 2021	10-Q	09 Aug 2022	2022	Q2
Q1 2021	$2,542,000	$7,000	-$69,000	-111%	01 Jan 2021	31 Mar 2021	10-Q	10 May 2022	2022	Q1
Q4 2020	$2,611,000	$2,584,000			01 Oct 2020	31 Dec 2020	10-K	17 Mar 2022	2021	Q4
Q3 2020		$185,000	-$366,000	-202%	01 Jul 2020	30 Sep 2020	10-Q	09 Nov 2021	2021	Q3
Q2 2020		$150,000	+$132,000	+733%	01 Apr 2020	30 Jun 2020	10-Q	10 Aug 2021	2021	Q2
Q1 2020		$62,000			01 Jan 2020	31 Mar 2020	10-Q	11 May 2021	2021	Q1
Q3 2019		$181,000			01 Jul 2019	30 Sep 2019	10-Q	10 Nov 2020	2020	Q3
Q2 2019		$18,000			01 Apr 2019	30 Jun 2019	10-Q	11 Aug 2020	2020	Q2

Fusion Pharmaceuticals Inc. Annual Income Tax Expense (Benefit) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2023	$787,000	+$2,624,000		01 Jan 2023	31 Dec 2023	10-K	20 Mar 2024	2023	FY
2022	$1,837,000	-$1,719,000	-1457%	01 Jan 2022	31 Dec 2022	10-K	20 Mar 2024	2023	FY
2021	$118,000	-$2,729,000	-105%	01 Jan 2021	31 Dec 2021	10-K	16 Mar 2023	2022	FY
2020	$2,611,000	+$2,360,000	+940%	01 Jan 2020	31 Dec 2020	10-K	17 Mar 2022	2021	FY
2019	$251,000			01 Jan 2019	31 Dec 2019	10-K	25 Mar 2021	2020	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.